Important note: Information in this article was accurate in 2003. The state of the art may have changed since the publication date.
PRNewswire - November 25, 2003
The site contains easy to read hepatitis B educational materials in English and several Asian languages, links to national events for healthcare providers, selected research on EPIVIR-HBV, and links to other hepatitis B education sites.
EPIVIR-HBV is approved in the US for the treatment of chronic hepatitis B associated with viral replication and active liver inflammation in adults and children ages 2 to 17 years. The recommended oral dose of EPIVIR-HBV for treatment of chronic hepatitis B in adults is 100mg once daily. The safety and effectiveness of treatment beyond one year and long-term treatment benefits have not been established. The optimal duration of treatment is not known. EPIVIR-HBV is not a cure for hepatitis B and has not been shown to reduce the risk of transmission of HBV to others.
Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases have been reported with the use of nucleoside analogues alone or in combination, including lamivudine and other antiretrovirals.
Human immunodeficiency virus (HIV) counseling and testing should be offered to all patients before beginning EPIVIR-HBV and periodically during treatment, because EPIVIR-HBV Tablets and Oral Solution contain a lower dose of the same active ingredient (lamivudine) as EPIVIR(R) Tablets and Oral Solution used to treat HIV infection. If treatment with EPIVIR-HBV is prescribed for chronic hepatitis B for a patient with unrecognized or untreated HIV infection, rapid emergence of HIV resistance is likely because of subtherapeutic dose and inappropriate monotherapy.
Patients taking EPIVIR-HBV should be monitored by a physician.
Deterioration of liver disease has been reported in some patients when treatment with EPIVIR-HBV was discontinued. Emergence of resistance hepatitis B virus and worsening of disease can occur during treatment.
Please visit http://www.hepatitisbhelp.com for more details, including the complete Prescribing Information for EPIVIR-HBV.
Facts About Hepatitis B
The virus is transmitted through direct contact with blood and other bodily fluids. The hepatitis B virus (HBV) targets the liver and can eventually lead to cirrhosis of the liver (also known as scarring), liver failure, liver cancer and death. While uncommon in the general United States population (only 0.3% of the general population has chronic HBV and liver cancer does not rank among the ten most common cancers), the statistics for the Asian/Pacific Islander (API) community are vastly different. One in ten APIs in the US are infected with hepatitis B, one in four of whom, if left untreated and unmonitored, will die from liver cancer, failure, and/or cirrhosis of the liver, according to the Centers for Disease Control (CDC) and Asian Am Pac Isl J Health, 2001;9:141-152.
About GSK
GlaxoSmithKline -- is one of the world's leading research-based pharmaceutical and healthcare companies. Visit GlaxoSmithKline at http://www.gsk.com or http://www.hepatitisbhelp.com .
SOURCE GlaxoSmithKline
Web Site: http://www.gsk.com http://www.hepatitisbhelp.com
031125
PR031163
Copyright © 2003 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .